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1. Introduction 
Colorectal cancer (CRC) is the third most common form of cancer and the third leading cancer 
killer for both genders in the United States (American Cancer Society, 2011). In 2011, the 
American Cancer Society estimates 141,210 new cases in the U.S. and 49,380 deaths due to 
CRC (American Cancer Society, 2011). Similarly, the World Health Organization estimates 
over 940,000 new cases occurring annually worldwide (World Health Organization, 2003), and 
nearly 610,000 died from CRC in 2008 (World Health Organization, 2011).  
Colorectal cancer is often found in people older than fifty, and its mortality rates are higher 
each year than HIV/AIDS and breast cancer combined (Colon Cancer Prevention Project, 
2011). The age-specific colorectal cancer risk rises continuously with advancing age 
(National Cancer Institute, 2011). CRC is also one of the most preventable among cancers, 
studies show that regular screening could substantially reduce mortalities (Kronborg et al., 
1996, Mandel et al., 1993, 1999). The reason is that colorectal cancer can take 5-15 years to 
develop, and screening exam, such as digital rectal exam (DRE), colonoscopy, flexible 
sigmoidoscopy (FSG) and faecal occult blood test (FOBT), can detect polyps before the 
cancer develops (Screen for Life: National Colorectal Cancer Action Campaign, 2009).  
The current guidelines in the U.S. for CRC include several options among men and women 
aged 50 and older at average risk (American Cancer Society, 2011). Many considerations are 
needed when following the guidelines, including risk factors, type of test, and test interval 
including flexible sigmoidoscopy, colonoscopy, double-contrast barium enema, computed 
tomographic colonography, faecal occult blood test and stool DNA test (American Cancer 
Society, 2011).  However, the acceptance of people about CRC screening has been low in the 
U.S. In most areas of the U.S., less than half of the population is in compliance with 
recommended CRC guidelines (American Cancer Society, 2011), and only one-third 
colorectal cancers are being diagnosed at an early and treatable stage, due to lack of 
screening or lack of disease symptoms (ARUP Laboratories, 2010).  
The purpose of colorectal cancer screening is to detect early stage of the disease before 
clinical symptoms take place. CRC has a 90% treatable rate when detected early, therefore 
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screening saves lives (Colon Cancer Prevention Project, 2011). Prevention efforts in the 
population requires reliable estimates of the sensitivity of the test, the sojourn time of the 
disease, the transition probabilities from the disease-free state to the preclinical state, the 
lead time of the disease and the indirect effects in the screening per se in the estimates of 
rates of the disease.  
The aim of this chapter is to introduce the concept of probability modelling in colorectal 
cancer screening, and the statistical methods developed by the authors in this area (Wu et 
al., 2005, 2007, 2009a, 2009b). We will estimate these essential components from a population 
based perspective. In section 2, we provide the definition, model, methods and application 
of essential parameters needed when estimating indicators of cancer screening. In section 3, 
we provide the methods and application for estimating the distribution of the lead time in 
cancer screening. In section 4, we provide the definition, methods and application when 
evaluating the long term screening outcomes in CRC. Finally, conclusions and 
recommendations for future research are provided in section 5. We will focus on one 
particular test, the faecal occult blood test (FOBT). FOBT has been used as a sign of colon 
cancer, given that tumours tend to bleed and blood in the stool can be detected using this 
test. We will apply our methods to the Minnesota Colorectal Cancer Control Study 
(MCCCS) (Mandel et al., 1999), to inform the readers about the benefits of probability 
modelling in colorectal cancer screening using FOBT, as well as reached recommendations 
for the test.  
The Minnesota Colorectal Cancer Control Study (MCCCS) was carried out between 1976 
and 1982 in Minnesota, U.S.A. (Mandel et al., 1999). Approximately 46,000 subjects were 
randomized to receive either: five annual FOBT screenings, three biennial FOBT screenings 
or no screening (usual care at the time of the study). Each screening cycle consisted of six 
hemoccult slides (Hemoccult®, Beckman Coulter, Palo Alto, California); about 83% of slides 
were re-hydrated. If any of the slides was positive, then the screen was considered positive 
and a definitive follow-up exam was done, including colonoscopy (Mandel et al., 1999). Due 
to a lower than expected death rate among the usual care group, the investigators resumed 
screening between 1986 and 1992. We restricted this analysis to the annual group and to the 
original five screenings.  
2. Sensitivity, sojourn time and transition probability in colon cancer 
screening 
We assume that the disease develops by progressing through three states, denoted by 
0 p cS S S  . 0S represents the disease-free state. pS represents the preclinical disease state, 
in which an asymptomatic individual unknowingly has disease that the screening exam can 
detect. Similarly, cS  represents the clinical state when the disease manifests itself in clinical 
symptoms.  
Sensitivity is the probability that the screening exam is positive given that the individual is 
in the preclinical state pS . The sensitivity cannot be easily estimated from data collected 
during screening, but can be estimated using probability modelling (Wu et al., 2005, 2009b). 
We exemplify the rationale for this issue using Table 1. Let us assume the data in Table 1 is 
generated from a single screening study. It is neither cost effective nor ethical to obtain a 
biopsy from each individual with a negative screening result. Therefore, the numbers 21n
and 22n  are not available; but 11n , 12n  and 21 22n n are available information. Using the 
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definition, an estimator of sensitivity should be 11 11 21/( )n n n . However, since the number 
21n is unknown, it cannot be obtained directly from data collected in the screening study.  
 
Screening Result 
Disease Status 
Cancer Non-Cancer 
Positive (+) True Positive ( 11n ) False Positive ( 12n ) 
Negative (-) False Negative ( 21n ) True Negative ( 22n ) 
Table 1. Illustration of different kinds of counts in a screening study 
Sojourn time refers to the time beginning when the disease first develops until the 
manifestation of clinical symptoms, which is the time length in the preclinical state. For 
individuals diagnosed with cancer by screening exams, they will be treated immediately; 
hence the onset of the clinical state cS is not observable. For individuals diagnosed with 
cancer between screenings (the interval case), though the onset of the clinical state is 
available, the onset of the preclinical state is still unknown. Therefore, estimation of the 
sojourn time distribution is difficult from data collected in screening studies. However, the 
sojourn time duration can be estimated under model assumptions, the preclinical phase of 
colorectal cancer may last more than 5 years (American Cancer Society, 2011, Prevost et al., 
1998).  
The transition probability into the preclinical stage is the probability density function (PDF) 
of making a transition from the disease-free state to the preclinical state. It is continuously 
changing with one’s age (Wu et al., 2009a) on CRC, and is difficult to estimate without 
proper modelling.  
These three parameters are the key parameters for the estimation of other important 
indicators in cancer screening, and they cannot be easily estimated from data. We will 
briefly review the age-dependent likelihood method that we used in estimating these three 
parameters, and provide the key result using the MCCCS data (Wu et al., 2005, 2009b). 
2.1 Model and method 
Consider a cohort of initially asymptomatic individuals who enrolled in a screening 
program. The sensitivity is (t), where t is the individual’s age at the screening exam. The 
probability density function (PDF) of making a transition from 0S to pS at age t is ( )w t . Let 
( )q x  be the probability density function of the sojourn time in pS . Let ( ) ( )
z
Q z q x dx

   which 
is the survivor function of the sojourn time in the preclinical state pS .  
Consider a cohort of men or women in the study of interest who are all aged 0t at study 
entry, and a protocol for K ordered screening exams occurring at ages 0 1 1 ,Kt t t   
where 0it t i   for annual screening exams. Define the i-th screening interval as the time 
interval between the i-th and the (i+1)-th screening exams 1( , ),i it t  i=1, 2,, K-1. We let 
1 0.t   For each screening exam, let 0,i tn  be the total number of individuals in this cohort 
examined at the i-th screening, 
0,i t
s  is the number of diagnosed and confirmed cancer cases 
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at the i-th screening exam, and 
0,i t
r is the number of cases diagnosed in the clinical state cS
within the interval 1( , )i it t , the interval cases. 
The likelihood function for each gender cohort is: 
 0 0 0 0 0
0 00 0
0 1
1k,t k,t k,t k,t k,t
K
s r n s r
k,t k,tk,t k,t
t k
L D I ( D I )
 

    .               (1) 
To facilitate the understanding of this likelihood function, we will describe it in terms of the 
MCCCS age groups. In the MCCCS, the initial age of participants varied from 28 to 90 years 
old, among men, and 36 to 93 years old, among women, so this is the range of 0t . Because 
the MCCCS required five annual FOBT screenings, K = 5. The
0,k t
D is the probability that an 
individual will be diagnosed at the k-th scheduled exam given that she/he is in pS  (see 
equation 2 and 3); and the
0,k t
I  is the probability of being an incident case in the k-th 
screening interval (see equation 4). 
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Where ( )i it     in the above formulae. We modelled the age effect t and the time 
duration x in the preclinical state very carefully using a parametric model stated in  
equation 5. 
 
0 1
2 2
1
2
1
( ) ,
1 exp( * ( ))
0.1
( ) exp{ (log ) /(2 )},
2
( ) .
(1 ( ) )
t
b b t m
w t t
t
x
q x
x
 


 
 


    
  
 
           (5) 
Where m is the average age-at-entry in the study and 20 1, , , , ,b b      are unknown 
parameters to be estimated. For simplicity, we will include these parameters in a vector 
form as 20 1( , , , , , )b b     . If 1b 0 , then ( )t  will be a monotone increasing function of 
age t. Usually, researchers can establish an upper bound for ( )w t  from pilot studies or from 
health department data. For example, in the MCCCS, we picked 10% as a reasonable upper 
bound for ( )w t because the lifetime risk of being diagnosed with colorectal cancer reported 
by the National Cancer Institute (SEER Cancer Statistics Review 1975-2007, 2010) for years 
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2005-2007 was about 4.97% for females and 5.30% for males. Wu et al. 2005, 2009b shows the 
detailed justifications on how these age effect functions were chosen. Models in equation 1-5 
were estimated using programs C/C++ (Silicon Graphics, I, 2003, Stroustrup, B, 2011) and 
we applied the likelihood separately for men and women in the MCCCS. Markov Chain 
Monte Carlo (MCMC) was used to generate random samples from the joint posterior 
distribution of the parameters in the likelihood for Bayesian inference (Wu et al., 2005, 
2009b). The posterior distribution within the MCMC was partitioned into four sub-chains, 
e.g. sampling the posterior distribution for 20 1( , ), , ,( , )b b     separately. Non-informative 
priors were used for all parameters (Wu et al., 2009b). Each MCMC was run for 20,000 steps; 
after a burn-in of 15,000 iterations, then posterior samples were collected every 20 steps, 
which finally provided 250 samples from each chain (Wu et al., 2009b). Because four over-
dispersed chains were simulated using MCMC, a pool of 1000 posterior samples were used 
for the analysis presented below. These Bayesian posterior samples are notated as *j .  
Bayes estimates of the highest posterior density (HPD) interval were also computed, which 
are similar to confidence interval from a frequentist perspective and also known as credible 
intervals from the Bayesian perspective. 
2.2 Results 
The original FOBT screening data from MCCCS for each age group, male and female, are 
published in table 1 and 2 in Wu et al. 2009b. The posterior estimates for parameters   and 
the standard errors for each gender are listed in table 3 in Wu et al. 2009b. The age-
dependent Bayesian estimates of the sensitivity  and the transition density ( )w t  for males 
and females are listed in table 2 and 3 here. 
 
Age 
Sensitivity   Transition probabilitya for ( )w t  
Median Mean S.E. Median Mean S.E. 
30 0.117 0.325 0.372 0.024 0.113 0.190 
35 0.192 0.361 0.368 0.090 0.207 0.258 
45 0.458 0.494 0.331 0.488 0.562 0.332 
55 0.791 0.749 0.213 1.101 1.122 0.278 
65 0.943 0.863 0.187 1.594 1.597 0.381 
75 0.980 0.879 0.191 1.683 1.692 0.467 
85 0.994 0.868 0.219 1.474 1.442 0.364 
aThe unit is 310 . 
Table 2. Bayesian posterior estimates of   and ( )w t for male participants. 
The sensitivity appears to increase with age for both male and female. A Bayes hypothesis 
test of 0 1: 0H b  versus 1 1: 0H b   showed that for males, the posterior probability of a 
positive slope was 1( 0| ) 0.806P b Data  ; for females, this posterior probability of a positive 
slope was 0.941.  
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The age-dependent transition probability was itself a sub-pdf from our model assumption. 
The posterior mean transition probability varied from 30.113 10  to 31.707 10  for males 
aged 30 to 90 and varied from 30.069 10 to 32.009 10  for females aged 40 to 90. The 
transition probability was not a monotone function of age, having a single maximum at age 
72 for males and a single maximum at age 75 for female.   
 
Age 
Sensitivity   Transition probability a for 
Median Mean S.E. Median Mean S.E. 
45 0.333 0.418 0.315 0.113 0.162 0.161 
55 0.802 0.769 0.191 0.600 0.624 0.228 
65 0.976 0.920 0.122 1.413 1.427 0.273 
75 0.996 0.955 0.093 1.968 2.009 0.468 
85 0.999 0.964 0.098 1.931 1.946 0.392 
aThe unit is 310 . 
Table 3. Bayesian posterior estimates of  and ( )w t  for female participants. 
The posterior mean sojourn time was 4.08 years for males and 2.41 years for females, with a 
posterior median of 1.66 years for males and 1.88 years for females. The 95% HPD interval 
was (0.97, 20.28) for males and (1.15, 5.96) for females. This shows that CRC may have a 
large variation in sojourn time, as oncologists believe that CRC usually has a long sojourn 
time more than 5 years.  
3. Distribution of the lead time in colorectal cancer screening 
The goal of screening is to catch the disease before clinical symptom appears. This means 
that the detection and removal of any precancerous growth is important as well as the 
diagnosis of cancer at an early stage. To understand this, several time events are essential to 
prevention efforts and they will be described briefly here. If a person enters the preclinical 
state ( pS ) at age 1t , and his/her clinical symptoms present later at age 2t , then 2 1( )t t is 
the sojourn time in the preclinical state. If a person is offered a screening exam at some time 
point t within the interval 1 2( , )t t , and cancer is diagnosed, then the length of the time 
2( )t t is the lead time. We consider lead time as the time gained by screening for that 
particular person. 
3.1 Methods 
We will briefly review the probability distribution of the lead time derived under a 
progressive disease model (Wu et al., 2007, 2009a). Assume there are K ordered screenings 
that, for a specific individual, occur at ages 0 1 1Kt t t    . The lead time distribution is a 
conditional distribution given that someone will develop clinical disease before death. We 
let D represent a Bernoulli random variable, with 1D  indicating the development of 
clinical disease and 0D   indicating the absence of the clinical disease before death. We use 
L to denote the lead time. We consider the lead time to be zero for individuals whose disease 
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is not detected by the regular screening exam but who develops clinical symptoms between 
exams. The distribution of the lead time is a mixture of the conditional probability
( 0| 1)P L D  and the conditional probability density function ( | 1)Lf z D  , for any
00 z T t   . Here, T represents the span of the human life, which is a fixed upper bound, 
and 0t  is the individual’s age at his/her initial screening exam. We define the same
( ), ( ), ( ), ( )t w t q x Q x as in Section 2.1. The distribution for the lead time was derived and 
presented in equation 6 (Wu et al., 2007, 2009a). 
 
( 0, 1)
( 0| 1)
( 1)
P L D
P L D
P D
    
 
and 
( , 1)
( | 1)
( 1)
L
L
f z D
f z D
P D
   .                (6) 
Where
0
0
00
( 1) ( )[ ( ) ( )] ( )[1 ( )]
t T
t
P D w x Q t x Q T x dx w x Q T x dx         , is the probability of 
developing colorectal cancer in one’s life time after age 0t .  
The lead time is zero if and only if the individual is an interval case, therefore the joint 
probability ,1 ,2 ,( 0, 1) K K K KP L D I I I      , where ,K jI is the probability of an interval 
case within the interval 1( , )j jt t , and it was derived as:  
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for all j=1, 2… K, with ( )i it   is the sensitivity at age it .  The joint PDF ( , 1)Lf z D  in 
equation 6 was derived and presented as:  
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 (8) 
Where 1( , ), 2,j jz T t T t j K     ; and when j=1, it is simplified as: 
            
0
0 00
( , 1) ( ) ( )
t
Lf z D w x q t z x dx    , if 1 0( , )z T t T t    .                 (9) 
We used the posterior samples *j estimated from equation 5 to project the lead time 
distribution for the male and female participants. To do this, the posterior predictive 
distribution of the lead time can be estimated by MCMC (Wu et al., 2009a) as stated in 
equation 10.  
 
*1( | ) ( , | ) ( | , ) ( | ) ( | ).j
j
f z Data f z Data d f z Data f Data d f z
n
                 (10) 
Where *( | )jf z   represents the mixture distribution in equation 6. The sample size n is 1000 
in section 2 from the MCMC.  
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3.2 Results 
We applied our method to make predictive inference of the lead time using FOBT for males 
and females. We assumed for this simulation that the initial age is 50, and an ending age of 
80. It is clear that the lead time distribution is a function of the sensitivity, the sojourn time 
distribution, the transition density, the screening frequency, and the initial age and ending 
age. Accurate estimation of the sensitivity, the sojourn time distribution and transition 
density were acquired from MCCCS study in section 2. Now, we plugged the estimates 
obtained from Section 2 into the simulation equation 10 in Section 3.1, leading to the 
estimation of the lead time distribution under different screening scenarios. In other words, 
we estimated what the results would be if people were screened at different screening 
intervals. The results are summarized in table 2 in Wu et al. 2009a. The time interval 
between screens was 6, 9, 12, 18 and 24 months, within ages 50 ( 0t ) and 80 years ( T ). Also, 
the density curves for the lead time are shown in Figure 2 and 3 in Wu et al. 2009a for 
different screening intervals for both males and females. From those results, if a man begins 
annual screening (i.e.  = 12 months) when he is 50 years old and continues until he reaches 
80, then there is a 18.87% chance that he will not benefit from early detection by the 
screening program if he develops colorectal cancer during those thirty years. His chance of 
no-early-detection from the screening program decreases to 6.45% for screening exams 
conducted 6 months apart. While for females, the chance of no-early-detection is 9.48% for 
annual screenings and 2.39% for screening every 6 months.  
Also, Table 2 in Wu et al. 2009a showed that the mean lead time increases as the screening 
time interval decreases for both males and females. In other words, more screening exams 
will contribute to a longer lead time, which would translate to treatment of the disease at an 
earlier stage and, potentially improved prognosis. The increase in the mean lead time is 
partly due to the smaller point mass for zero lead time when screening exams are closer 
together. The standard error of the lead time decreases as the time between screening exams 
increases. Similarly, Table 2 in Wu et al. 2009a revealed that the standard deviation for the 
lead time was larger than the mean lead time (Wu et al., 2009a). In the same table, the mode 
of the lead time, which is the value that is most likely taken by the lead time when it is 
positive, was 0.68 years (or 8 months), corresponding to screening exams every 6 months for 
males, and 0.96 years (or 11.5 months) for females (Wu et al., 2009a). With annual exams, the 
mode value for the lead time is 0.60 years (6 months) for males and 0.78 years (9.4 months) 
for females. 
4. Evaluating long term screening outcomes in colorectal cancer   
Recently there have been heated arguments in the topic of over diagnosis, the diagnosis of 
``disease” that will not cause symptoms or death during a patient’s lifetime (Lichtenfeld, J L, 
2010). Some profound questions should be asked with regards to over diagnosis. How do 
we evaluate the long-term outcomes due to continuous regular screening? Will regular 
screening exams contribute to a greater chance of over diagnosis? What are the percentages 
of over diagnosis and true-early-detection among the screen-detected cancer patients? How 
should the probability of no-early-detection and the probability of disease-free-life be 
estimated?  
Some research has been done in the area of over diagnosis. However, the majority of 
research in this area has been based on observational studies, and mainly in breast cancer 
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(Day, 2005, Duffy et al., 2008, Welch & Black, 2010, Zackrisson et al., 2006), there is little 
reference to this problem in colorectal cancer. The flaws of using observational studies are 
obvious: (a) the result based on one study cannot be extended to other scenarios. The 
reason is that for one particular study, with one particular screening interval, the result 
may be correct, however, one cannot use this result to make inference for studies with 
different screening intervals or different cohorts without probability modelling. On the 
other hand, it is clear that it is of great value to policy makers to know how the proportion 
of over diagnosis is changing with screening frequency, sensitivity of the screening 
modality, and other risk factors; (b) using observational studies usually needs a long 
follow-up period to collect cancer incidence data from both the screening group and the 
control group, because most of the observational studies compares the incidence rates in 
the two groups to estimate over diagnosis. This is not cost effective, and the inference 
maybe biased.  
To overcome these flaws, we used probability modelling, and instead of dealing with over 
diagnosis alone, we will address the long-term outcomes for the whole cohort, with over 
diagnosis as one outcome. All initially superficially healthy participants will be classified 
into four mutually exclusive categories: true-early-detection, no-early-detection, over 
diagnosis and symptom-free-life (Wu & Rosner, 2010).  
- Case 1 (Symptom-free-life or SympF): A person who took part in screening exams 
that never detected colorectal cancer, and ultimately the person died of other causes.  
- Case 2 (No-early-detection or NoED): A person who took part in screening exams, but 
whose disease manifest itself clinically and was not detected by screening. 
- Case 3 (True-early-detection or TrueED): A person whose colorectal cancer was 
diagnosed at a scheduled screening exam and whose clinical symptoms would have 
appeared before death.  
- Case 4 (Over diagnosis or OverD): A person who was diagnosed with colorectal cancer 
at a scheduled screening exam but whose clinical symptoms would NOT have 
appeared before death.  
Every participant who takes part in the screening will eventually fall into one of these four 
outcomes. It is hoped that this will provide a systematic approach and a frame work for the 
evaluation of long term outcomes in cancer screening.   
4.1 Methods 
For an initially asymptomatic individual taking K screenings at their ages 0 1 1Kt t t    , 
the conditional probability for each of the four cases was derived, given that their lifetime 
1( )K KT t t    and presented in equations 11-15.   
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Where 
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,K jI  is the probability of being an interval case in the interval ( 1 ,j jt t ) in a sequence of K 
screening exams. 
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For an individual currently at age 0t , his/her lifetime is random, and it would not be 
practical to fix the number of screening exams to any fixed number K . If, however, he/she 
follows a pre-planned screening schedule, or, more simply, if he/she plans to be screened 
every 12, 18, or 24 months, then the probability of each outcome when his/her lifetime T is 
longer than 0t can be obtained using equation 16. 
 
0
0 0( | ) ( | ( ), ) ( | )T
t
P Case i T t P Case i K K t T t f t T t dt

     , for i = 1,2,3,4.    (16) 
Where the lifetime probability density function 0( | )Tf t T t  is defined in equation 17.  
 0
0 0
( ) ( )
( | )
( ) 1 ( )
T T
T
T
f t f t
f t T t
P T t F t
    , if 0t t .             (17) 
The probability ( | ( ), )P Case i K K t T t   was derived in equations 11-15, and the number 
of screening exams  0( ) ( ) /K K t t t    , is the largest integer that is less than or equal to 
0( ) /t t  . Hence, K is a random variable as well, taking integer values and changing 
with one’s lifetime T . It was proved that for any screening number K ,
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4
0
1
( | , ) 1
i
P Case i A T t

  . Where the event A = {an individual is asymptomatic of 
colorectal cancer before age 0t } and 
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t t
P A T t w x dx w x Q t x dx                   (18) 
The probability for each of the four cases is a function of the sensitivity ( )t , the transition 
probability density ( )w t , the sojourn time distribution ( )q x , a person’s age at the first 
screening 0t  and his/her future screening interval  . The age-dependent sensitivity ( )t , 
the age-dependent transition probability, and the sojourn time distribution ( )q x , were 
estimated from the MCCCS data (Wu et al., 2009a) and were given in Section 2.2.  
Given the MCCCS data, the posterior predictive probability of each case can be estimated 
as: 
 
*
0 0
1
( | , ) ( | , ).j
j
P Case i T t MCCCS P Case i T t
n
                (19) 
Where *j  is the MCMC random sample drawn from the posterior distribution and n  1000 
is the posterior sample size.  
Furthermore, we defined a diagnosed case as when either an interval clinical incident case 
or a screen-detected case happens in a study. Researchers may be interested in the 
proportion of “no-early-detection”, “true-early-detection” and “over diagnosis” given that it 
is a diagnosed case. For example, among females, what are the estimated probabilities of 
“no-early-detection”, given that a woman has been diagnosed with colorectal cancer, either 
through scheduled screening exam or not. Last but not least, researchers are most interested 
in the probabilities of “true-early-detection” and “over diagnosis” given that it is a screen-
detected case. All of these conditional probabilities were also estimated using equations 12-
19 using the definition of conditional probability.  
4.2 Results 
In section 2.2 we estimated *j  as a MCMC random sample drawn from the posterior 
distribution. A total of 1000 posterior samples were put into equation 19 to conduct the 
Bayesian inference. This Bayesian inference assumed that there is a program consisting of 
periodic screening exams from three hypothetical cohorts of asymptomatic individuals. 
Those cohorts have initial ages of 40, 50 and 60 at the first screening exam for males or 
females. For each group, we examined various screening frequencies, with screening 
interval  = 12, 18, and 24 months. For the lifetime distribution, we used the actuarial life 
table from the Social Security Administration, which was published online for year 2007 
(Social Security Administration, 2011). The actuarial life table is based on mortality and 
provides the probability of death within one year from age 0 to age 119 years old.  
Based on that life table, we derived the conditional lifetime distribution 0( | )Tf t T t  (Wu 
and Rosner 2010) and estimated the probabilities of each of the four cases, i.e. 
0( | , , )P Case i A T t MCCCS , using the estimations of sensitivity, sojourn time distribution, 
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and transition probability obtained from the MCCCS data for males and females. Overall, 
the proportion of over diagnosis was very small, less than 0.3% for any age and gender.   
The probability of “true-early-detection” for males was between 1.91% (at 60 years old, 
with 24 months as screening interval) and 3.28% for 40 years old, with 12 months as 
screening interval. Correspondingly, the probability of “true-early-detection” for females 
was between 2.75% for 60 years old, with screening interval of 24 months and 3.76% for 40 
years old, with screening interval of 12 months. Regardless of the age, the probability of 
“true-early-detection” slightly decreased as the screening time interval increased and 
overall, the probability of “true-early-detection” was consistently lower for males than for 
females.  
The probability of “no-early-detection” for males was between 0.53% for 60 years old, with 
screening interval of 12 months to 1.95% for 40 years old, with screening interval of 24 
months. The probability of “no-early-detection” for females was between 0.29% for 60 years 
old, with screening interval of 12 months to 1.34% for 40 years old, with screening interval 
of 12 months. In general, the probability of “no-early-detection” slightly increased as the 
screening interval increased, and slightly decreased as the age at initial screening was older. 
The probability of “symptom-free-life” was very large (e.g. over 95%). Regardless of age or 
gender, the probability of “symptom-free-life” was almost constant for any number of 
months between two screenings. For example, among 50 years old males, the probability of 
“symptom-free-life” was 95.84% if 12 months was the screening time interval; 95.87% if 18 
months was the screening time interval; and 95.90% if 24 months was the screening time 
interval. The sum of the probability of all four cases should add up to 1, and it was observed 
in the simulation, the total probability is above 0.998, due to simulation accuracy, this is 
clinically insignificant. 
The box plot of the probability for each case when 0t =60 is given in Figure 1. Within each 
box plot, the three left-hand-side boxes represent females and the three right-hand-side 
boxes represent males, and these probabilities are presented at different screening 
intervals. We decided to present the box plots when the initial screening age was 60 but 
similar box plots were observed for 0t = 40 and 50. Again, we see in Figure 1 that the 
probability of “symptom-free-life” and the probability of “over diagnosis” are pretty 
stable over the screening time intervals, regardless of gender. The probability of “no-
early-detection” increased monotonically with the screening time interval, while the 
probability of “true-early-detection” decreases monotonically with the length of the 
screening time interval.  
The estimated conditional probabilities of “no-early-detection”, “true-early-detection” and 
“over diagnosis”, given that it is a diagnosed case, for females and males were estimated.  
Among the initial age of 40 years-old women group, the percentage of over diagnosis given 
that it was a diagnosed cancer case was 5.04%, if she was screened every 24 months apart; 
and 6.50%, if she was screened every 12 months apart.  Similarly, the estimated conditional 
probabilities of “true-early-detection” and “over diagnosis” given that it is a screen-detected 
case, for females and males were also estimated. Among the 40 years-old women initial age 
group, the percentage of over diagnosis among the screen-detected cases was 6.75% (95% 
HPD: 2.56%-19.27%), if screened every 24 months apart, and 7.12% (95% HPD: 2.76%-
19.91%), if screened every 12 months apart.  
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Fig. 1. The box plot of the estimated percentage for each outcomes, with 0t =60. 
Figure 2 shows the probabilities of “true-early-detection” and the probability of “over 
diagnosis” among those whose cancer would be diagnosed by regular screening exam for 
the initial-age-60 group of both genders. In Figure 2, the screening time interval for males 
and females are presented for 12, 18 and 24 months. The estimated mean percentage for 
“true-early-detection” and “over diagnosis” given that it is a screen-detected case was 
similar for males and females. However, the 95% C.I. for males were much larger than that 
for females; this indicates that there is more uncertainty of these probabilities for males.  
5. Discussion  
We presented some results in probability modelling and statistical inference in colorectal 
cancer screening, using FOBT as an example. As we have shown in section 2, the three key 
parameters are the sensitivity of the screening modality, the transition probability of the 
disease, and the sojourn time distribution. All other parameters of interests can be expressed 
as a function of these three key parameters, hence accurate estimation of them is very 
important. These three key parameters are the building blocks in the cancer screening 
model, many researchers are striving to improve the modelling and get more accurate 
estimates of these parameters.  
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Fig. 2. Estimated percentage of true-early-detection and over diagnosis with its 95%HPD for 
0t =60.  
Although, other researchers have also estimated the sensitivity and the mean sojourn time in 
fecal Hemoccult testing, using data from Calvados, France between 1991 and 1994 (Prevost 
et al., 1998), their models are different from the progressive model that we used here. 
Prevost et al. (1998) modelled the incidence of cancer as a Poisson random variable, with 
different parameter value for the mean of the Poisson distribution (Prevost et al., 1998). 
Another difference is that their sojourn time was assumed to follow an exponential 
distribution. They reported that the mean sojourn time increases with age, which is 
approximately two years among 45-54 years-old, 3 years among 55-64 years-old, and 6 years 
among 65-74 years-old (Prevost et al., 1998). Their estimation of sensitivity decreases with 
age, which is approximately 75% among 45-54 years-old, 50% among 55-64 years-old, and 
40% among 65-74 years-old (Prevost et al., 1998).   
Church et al (1997) used the same Minnesota study (MCCCS) to estimate the sensitivity. 
However, their estimate of program sensitivity is about 90%, regardless of age (Church et 
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al., 1997). Our estimates are more accurate for different age groups as reported in section 2. 
There are other data sets that were used to estimate the FOBT screening sensitivity and 
mean sojourn time. For example, French data reported by Launoy et al. (1997) estimated the 
FOBT mass-screening sensitivity to be about 50% (Launoy et al., 1997). Their estimated 
mean sojourn time was longer than our results, between 4.5 and 5 years for all combined 
cancer cases. Also, these researches showed that the estimation of the sensitivity and the 
sojourn time maybe negatively correlated (Launoy et al., 1997). Better modelling strategies 
are needed to handle this situation. We plan to explore solutions accounting for the negative 
correlation between the sensitivity and the sojourn time to solve this problem.  
There is little research in the topic of lead time bias or the lead time distribution except in 
Wu et al. (2009) (Wu et al., 2009a). Since there is convincing evidence that FOBT and/or 
other colorectal screening modalities can significantly reduce mortality (Mandel et al., 1999), 
the U.S. Preventive Services Task Force has recommended screening people between 50-75 
years-old since 2008 (U.S.Preventive Services Task Force, 2008). Unfortunately, the 
compliance to colorectal cancer screening is low in the U.S. and the world (Sarfaty & 
Wender, 2007). We hope the lead time results from our simulations and models (Section 3) 
can provide some helpful information to general audiences about the benefit of taking 
screening exams. 
There is almost no research in the topic of over diagnosis or long-term outcomes in 
colorectal cancer, to our knowledge. As the first of the baby boomer generation turns age 65 
this year, evaluating the long-term outcomes will provide useful information and great 
insights to policy makers. We hope our method will provide a frame work and a systematic 
approach for evaluation purposes. To explore this topic more, we will need to obtain more 
recent screening data. We are exploring if data from the Prostate, Lung Colorectal and 
Ovarian (PLCO) cancer screening trial can be released to us (National Cancer Institute 
Division of Cancer Prevention, 2011). 
Our future research topic includes three areas: (1) exploring the relationship between 
sensitivity and the sojourn time distribution, and building up a better modelling strategy for 
these three parameters; (2) exploring the optimal screening interval based on an individual’s 
screening history; and (3) exploring the survival benefit from screening after removing the 
lead time bias, hence we can have a better understanding of what we gained from screening. 
We hope the research will benefit the health of the general population. 
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